Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Krystal Biotech to Present at Chardan Annual Genetic Medicines Conference
-
AVROBIO, Inc. to Present at Chardan's 2nd Annual Genetic Medicines Conference
-
AVROBIO, Inc. to Present at Chardan's 2nd Annual Genetic Medicines Conference
-
Kodiak Sciences (KOD) IPO Opens Flat
-
Peter Lang Joins Chardan as Managing Director
-
Nightstar Therapeutics to Present at Chardan Genetic Medicines Conference
-
Nightstar Therapeutics to Present at Chardan Genetic Medicines Conference
-
Kodiak Sciences Inc. (KOD) Prices 9M Share IPO at $10/Sh
-
Kodiak Sciences Inc. Announces Pricing of Initial Public Offering
-
Ophthotech Corporation to Present at Chardan’s 2nd Annual Genetic Medicines Conference
-
MeiraGTx to Present at Upcoming Conferences
-
MeiraGTx to Present at Upcoming Conferences
-
Nightstar Announces Closing of Public Offering and Full Exercise of Underwriters’ Option
-
REGENXBIO to Present at the Chardan 2nd Annual Genetic Medicines Conference
-
Nightstar Announces Closing of Public Offering and Full Exercise of Underwriters’ Option
-
Regulus to Participate in Fireside Chat at the Chardan Genetic Medicines Conference
-
Arbutus to Present at Chardan’s Genetic Medicines Conference
-
Arbutus to Present at Chardan’s Genetic Medicines Conference
-
ProQR to Present at the Chardan Genetic Medicines Conference
-
CRISPR Therapeutics to Present at the Chardan Genetic Medicines Conference
-
Homology Medicines to Present at Upcoming Conferences
-
Abeona Announces Participation at Upcoming Conferences
-
Abeona Announces Participation at Upcoming Conferences
-
Teladoc (TDOC) PT Raised to $98 at Chardan Capital Markets
-
uniQure to Participate in Multiple Upcoming Industry Conferences
-
Nightstar Therapeutics plc (NITE) Prices 4M ADS Offering at $18/ADS
-
Nightstar Announces Pricing of Public Offering
-
Nightstar Announces Pricing of Public Offering
-
Tocagen to Participate in Four Investor Conferences in October
-
Fibrocell to Present at Upcoming Industry and Investor Conferences
-
Fibrocell to Present at Upcoming Industry and Investor Conferences
-
Audentes Therapeutics to Participate in Upcoming Investor Conferences
-
Ocugen to Present at Two Upcoming Investor Conferences
-
PTC Therapeutics to Participate at Upcoming Investor Conference
-
Arrowhead Pharmaceuticals to Present at Upcoming October 2018 Conferences
-
Rocket Pharmaceuticals Announces Participation at Upcoming Conferences
-
Arcturus Therapeutics to Present at October Investor Conferences
-
Sangamo Therapeutics Announces Participation At Upcoming Investor and Industry Conferences
-
Intellia Therapeutics to Present at October Healthcare Investor Conferences
-
Kodiak Sciences Inc. Announces Launch of Initial Public Offering
-
UPDATE: Chardan Upgrades KVH Industries (KVHI) to Buy
-
Megalith Financial Acquisition Corp. Announces Closing of Underwriters’ Over-Allotment Option in Connection with its Initial Public Offering
-
Megalith Financial Acquisition Corp. Announces Closing of Underwriters’ Over-Allotment Option in Connection with its Initial Public Offering
-
Exicure, Inc. (XCUR) Reports Positive Phase 1 Results for Lead Immuno-Oncology Asset
-
Axovant to Present at Two Upcoming Investor Conferences
-
Exicure Announces Positive Phase 1 Results for its Lead Immuno-Oncology Asset
-
BioSig Technologies (BSGM) PT Raised to $12.50 at Chardan Ahead of NASDAQ Uplisting
-
Chardan Advises NovellusDX in Cross-Border Biotech Merger
-
Cancer Genetics (CGIX) and NovellusDx Enter Definitive Agreement to Merge
-
Cancer Genetics and NovellusDx Sign Definitive Agreement to Merge

